
Ascendis Pharma can be satisfied with the progress it has made on several fronts regarding its new drug candidate.
The Danish, but US-listed, biotech company reports that it has recruited the required amount of patients for the company's phase III trial with the drug palopegteriparatide, also known as Transcon PTH, for the disease hypoparathyreoidism. The firm is also willing to let in patients who were prepped for the study in June, if they meet the required criteria.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app